WO1997011667A3 - Therapeutic applications using horse serum - Google Patents
Therapeutic applications using horse serum Download PDFInfo
- Publication number
- WO1997011667A3 WO1997011667A3 PCT/IB1996/001115 IB9601115W WO9711667A3 WO 1997011667 A3 WO1997011667 A3 WO 1997011667A3 IB 9601115 W IB9601115 W IB 9601115W WO 9711667 A3 WO9711667 A3 WO 9711667A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutic applications
- horse serum
- sera
- viral
- aids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96932773A EP0853486A4 (en) | 1995-09-25 | 1996-09-25 | Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases |
AU71431/96A AU7143196A (en) | 1995-09-25 | 1996-09-25 | Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US428195P | 1995-09-25 | 1995-09-25 | |
US60/004,281 | 1995-09-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997011667A2 WO1997011667A2 (en) | 1997-04-03 |
WO1997011667A3 true WO1997011667A3 (en) | 1997-06-12 |
Family
ID=21710013
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1996/001059 WO1997011666A2 (en) | 1995-09-25 | 1996-09-25 | Use of 2-mercaptoethanolamine (2-mea) and related aminothiol compounds and copper(ii)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases |
PCT/IB1996/001115 WO1997011667A2 (en) | 1995-09-25 | 1996-09-25 | Therapeutic applications using horse serum |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1996/001059 WO1997011666A2 (en) | 1995-09-25 | 1996-09-25 | Use of 2-mercaptoethanolamine (2-mea) and related aminothiol compounds and copper(ii)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP0858327A2 (en) |
JP (1) | JPH11514990A (en) |
AU (2) | AU6999096A (en) |
CA (2) | CA2233015A1 (en) |
WO (2) | WO1997011666A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994409A (en) | 1997-12-09 | 1999-11-30 | U.S. Bioscience, Inc. | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds |
US6384259B1 (en) | 1998-11-16 | 2002-05-07 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and dosage form |
JP2003510363A (en) * | 1999-10-04 | 2003-03-18 | カーター、ジョン | Pharmaceutical composition and use thereof |
US6811788B2 (en) | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
US7927612B2 (en) | 2000-01-19 | 2011-04-19 | Baofa Yu | Combinations and methods for treating neoplasms |
US6506413B1 (en) * | 2001-04-30 | 2003-01-14 | Joseph C. Ramaekers | Compositions for treating animal diseases and syndromes |
US7053072B2 (en) | 2001-05-11 | 2006-05-30 | Medimmune Oncology, Inc. | Methods for the administration of amifostine and related compounds |
FR2825923B1 (en) * | 2001-06-15 | 2006-04-07 | Oreal | NO-SYNTHASE INHIBITOR AND USES |
KR20030077743A (en) * | 2002-03-26 | 2003-10-04 | 변현규 | The serum of pregancy mare |
US7629333B2 (en) | 2002-03-29 | 2009-12-08 | Medimmune, Llc | Stable amorphous amifostine compositions and methods for the preparation and use of same |
WO2004024129A1 (en) * | 2002-09-10 | 2004-03-25 | Samir Chachoua | Induced remission therapy |
GB2398497A (en) * | 2003-02-19 | 2004-08-25 | Walcom Animal Science | Composition for improving immunity of animals |
US9125874B2 (en) | 2007-11-30 | 2015-09-08 | The Ramaekers Family Trust | Administration of transfer factor for improving reproductive health |
CN101138634A (en) | 2006-09-07 | 2008-03-12 | 于保法 | Composition for treating tumour |
EP2278984A4 (en) | 2007-11-30 | 2013-02-27 | Ramaekers Family Trust | Compositions and methods for enhancing fertility |
US20110311557A1 (en) * | 2009-02-11 | 2011-12-22 | Martin Heath Bluth | Reciprocal serum/plasma exchange for the treatment of cancer |
WO2016086070A1 (en) | 2014-11-26 | 2016-06-02 | Baofa Yu | Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4228127A (en) * | 1978-10-06 | 1980-10-14 | International Radioimmune Systems, Inc. | Kit for detecting human chorionic gonadotropin |
US5310653A (en) * | 1989-10-24 | 1994-05-10 | Board Of Regents, The University Of Texas System | Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4952607A (en) * | 1982-05-27 | 1990-08-28 | International Copper Research Association, Inc. | Copper complex for treating cancer |
US5057314A (en) * | 1988-09-30 | 1991-10-15 | Whitfill Craig E | Low molecular weight antiviral factors |
US5488042A (en) * | 1992-03-13 | 1996-01-30 | Arch Development Corporation | Method for protection against genotoxic mutagenesis |
DE4236069A1 (en) * | 1992-10-26 | 1994-04-28 | Werner Dr Bergmann | Homeopathic medicaments for treating HIV infections - prepd. by dilution of infected serum |
WO1994028934A1 (en) * | 1993-06-07 | 1994-12-22 | Center For Special Immunology | Adoptive immune reconstitution treatment for patients with acquired immunodeficiencies |
-
1996
- 1996-09-25 AU AU69990/96A patent/AU6999096A/en not_active Abandoned
- 1996-09-25 JP JP9513260A patent/JPH11514990A/en not_active Ceased
- 1996-09-25 EP EP96931214A patent/EP0858327A2/en not_active Withdrawn
- 1996-09-25 AU AU71431/96A patent/AU7143196A/en not_active Abandoned
- 1996-09-25 CA CA002233015A patent/CA2233015A1/en not_active Abandoned
- 1996-09-25 WO PCT/IB1996/001059 patent/WO1997011666A2/en not_active Application Discontinuation
- 1996-09-25 EP EP96932773A patent/EP0853486A4/en not_active Withdrawn
- 1996-09-25 CA CA002233445A patent/CA2233445A1/en not_active Abandoned
- 1996-09-25 WO PCT/IB1996/001115 patent/WO1997011667A2/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4228127A (en) * | 1978-10-06 | 1980-10-14 | International Radioimmune Systems, Inc. | Kit for detecting human chorionic gonadotropin |
US5310653A (en) * | 1989-10-24 | 1994-05-10 | Board Of Regents, The University Of Texas System | Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis |
Non-Patent Citations (19)
Also Published As
Publication number | Publication date |
---|---|
WO1997011666A2 (en) | 1997-04-03 |
EP0858327A2 (en) | 1998-08-19 |
JPH11514990A (en) | 1999-12-21 |
WO1997011667A2 (en) | 1997-04-03 |
AU6999096A (en) | 1997-04-17 |
CA2233445A1 (en) | 1997-04-03 |
EP0853486A4 (en) | 2001-09-26 |
CA2233015A1 (en) | 1997-04-03 |
WO1997011666A3 (en) | 1997-06-19 |
AU7143196A (en) | 1997-04-17 |
EP0853486A2 (en) | 1998-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997011667A3 (en) | Therapeutic applications using horse serum | |
EP0853486A3 (en) | Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases | |
AU2993297A (en) | Treatment of sickle cell disease, treatment of immune system diseases and other diseases normally associated with sickle cell anemia | |
BG101103A (en) | Mammalian telomerase | |
FR12C0004I2 (en) | ANTIBODIES TO HUMAN CTLA-4 ANTIGEN AND USE | |
MXPA02011656A (en) | Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods. | |
BG100293A (en) | 2,8-disubstituted quinazolinons | |
PL319021A1 (en) | Body weight modulators, appropriate nucleic acid and proteins and their diagnostic and therapeutic application | |
AU1685499A (en) | Polypeptide, their production and use | |
CA2212058A1 (en) | Preparation and use of a specific gaba-a.alpha.5 receptor ligand for treatment of alzheimer's disease | |
AU2990695A (en) | Mucin-derived proteins for the diagnosis, imaging, and therapy of human cancer | |
WO1996001614A3 (en) | Rna component of telomerase | |
WO1998019167A3 (en) | Cell stress regulated human mhc class i gene | |
AU9312198A (en) | Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer | |
AU2001285210A1 (en) | Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers | |
NZ338060A (en) | Use of bacterial cell wall extract for the manufacture of a medicament for treating a protozoal or parasitic disease | |
WO1997018790A3 (en) | Therapeutic and diagnostic agents for the treatment of microbial infections | |
AU9363398A (en) | Hepatitis c receptor protein cd81 | |
AU3927189A (en) | N-2,3-butadienyl tri- and tetraaminoalkane derivatives | |
EP0795332A3 (en) | Medical use of gamma-interferon in interstitial lung diseases | |
CA2271478A1 (en) | Tissue specific expression of retinoblastoma protein | |
FR2757864B1 (en) | ANTIBODIES SPECIFICALLY RECOGNIZING A NITROSYLATED PROTEIN, THEIR PREPARATION METHOD, THEIR THERAPEUTIC AND DIAGNOSTIC USE | |
AU1820499A (en) | Compounds and methods for the diagnosis and treatment of (b. microti) infection | |
DE59611307D1 (en) | NUCLEIC ACID MOLECULES COPYING PROTEINS THAT TRANSFER THE ADHESION OF NEISSERIA CELLS TO HUMAN CELLS | |
AU7974791A (en) | Identification of novel drugs and reagents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AU BB BG BR CA CN CU CZ EE FI GE HU IS JP KE KG KP KR LK LR LT LV MD MG MK MN MW MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AU BB BG BR CA CN CU CZ EE FI GE HU IS JP KE KG KP KR LK LR LT LV MD MG MK MN MW MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2233015 Country of ref document: CA Ref country code: CA Ref document number: 2233015 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996932773 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1996932773 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996932773 Country of ref document: EP |